44 completed, 7 terminated, 5 unknown, 2 active not recruiting. 64 Phase 2, 16 Phase 1, 4 Phase 3.
Follow Staphylococcal Infections: new trials by email Literature Review of Staphylococcal Infections trials Research Report on Staphylococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus Topical anti-Staphylococcus bacteriophage therapy, Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy - Diabetic Foot, Staphylococcal Infections | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Nīmes | 60 | 2026-09-01 | 2026-03-20 |
| Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia Clopidogrel, No antiplatelet treatment - Bacteremia Due to Staphylococcus Aureus | Phase 2 | Not yet recruiting | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 230 | 2026-06-01 | 2026-02-05 |
| A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa) AZD7760, Placebo - Staphylococcus Aureus | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 242 | 2024-12-30 | 2026-10-28 |
| Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection Phage therapy - Prosthetic Joint Infections of Hip, Staphylococcus Aureus Infection | Phase 1 / Phase 2 | Active not recruiting | University of Calgary | 1 | 2024-11-20 | 2025-06-11 |
| Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia Ertapenem, Placebo - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia | Phase 2 | Recruiting | Todd C. Lee MD MPH FIDSA | 60 | 2024-05-20 | 2026-11-02 |
| Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® IMP, Placebo - Surgical Site Infection, Staphylococcus Aureus Infection | Phase 1 / Phase 2 | Unknown | MB PHARMA s.r.o. | 52 | 2023-10-27 | 2024-03-19 |
| Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection FLU or CZO as continuous infusion, standard FLU or CZO intermittent bolus administration - Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI) | Phase 2 | Recruiting | University Hospital, Basel, Switzerland | 36 | 2023-10-26 | 2024-12-16 |
| Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI) Sa-5Ag half dose non-adjuvanted, Sa-5Ag full dose non-adjuvanted, Sa-5Ag half dose adjuvanted - Infections, Soft Tissue | Phase 2 | Completed | GlaxoSmithKline | 226 | 2022-11-16 | 2025-05-08 |
| Phage Therapy in Prosthetic Joint Infection Due to Staphylococcus Aureus Treated With DAIR. Anti-Staphylococcus aureus Bacteriophages - Infection of Total Hip Joint Prosthesis, Infection of Total Knee Joint Prosthesis | Phase 2 | Unknown | Phagenix | 64 | 2022-06-15 | 2022-06-22 |
| Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia AP-SA02, Placebo - Bacteremia, Staphylococcus Aureus | Phase 1 / Phase 2 | Completed | Armata Pharmaceuticals, Inc. | 56 | 2022-04-26 | 2026-03-23 |
| Nasal Photodisinfection in All Patients Presenting for Surgery for a Wide Range of Surgical Procedures methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation - Surgical Site Infections, Nosocomial Infection | Phase 2 | Completed | Ondine Biomedical Inc. | 322 | 2022-02-04 | 2022-08-22 |
| Phage Therapy for the Prevention and Treatment of Pressure Ulcers. Bacteriophage-loaded Microcapsule Spray, Placebo, Standard of Care - Pressure Ulcer | Phase 1 / Phase 2 | Unknown | Precisio Biotix Therapeutics, Inc. | 69 | 2022-01-01 | 2021-12-21 |
| DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia Cefazolin, Dalbavancin, Daptomycin - Staphylococcal Bacteraemia | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2021-04-22 | 2024-12-10 |
| Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers TP-102 - Diabetic Foot Ulcer, Pseudomonas Aeruginosa Infection | Phase 1 / Phase 2 | Completed | Technophage, SA | 20 | 2021-03-22 | 2022-10-04 |
| Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection XF-73, Placebo - Staphylococcal Infections, Surgical Site Infection | Phase 2 | Completed | Destiny Pharma Plc | 124 | 2019-08-29 | 2023-10-16 |
| Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo J. lividum - Atopic Dermatitis | Phase 2 | Terminated | DermBiont, Inc. | 9 | 2019-05-20 | 2021-06-18 |
| Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo ATx201, ATx201 GEL Vehicle - Impetigo | Phase 2 | Completed | UNION therapeutics | 210 | 2018-02-23 | 2018-07-31 |
| Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization NDV-3A, Placebo - Staphylococcus Aureus | Phase 2 | Completed | NovaDigm Therapeutics, Inc. | 382 | 2018-01-30 | 2020-01-29 |
| Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Hydroxychloroquine - Hidradenitis Suppurativa, Hidradenitis | Phase 1 / Phase 2 | Completed | Elena Gonzalez Brant, MD | 17 | 2017-09-28 | 2020-04-02 |
| Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia CF-301, Placebo - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 2 | Completed | ContraFect | 121 | 2017-05-23 | 2021-10-08 |
Showing 20 of 64. Sign in to see all of them.
Bacteremia (11) · Impetigo (9) · Sepsis (5) · Staphylococcal Skin Infections (5) · Abscess (4) · Cellulitis (4) · Dermatitis, Atopic (3) · Pneumonia, Staphylococcal (3) · Pseudomonas Infections (3) · Skin Diseases, Bacterial (3) · Surgical Wound Infection (3) · Bacterial Infections (2) · Diabetic Foot (2) · Furunculosis (2)
Bacterial Infections and Mycoses (64) · Gram-Positive Bacterial Infections (63) · Bacterial Infections (62) · Infections (62) · Pathologic Processes (24) · Pathological Conditions, Signs and Symptoms (24) · Skin and Connective Tissue Diseases (23) · Skin Diseases (21) · Inflammation (18) · Skin Diseases, Infectious (17) · Skin Diseases, Bacterial (14) · Systemic Inflammatory Response Syndrome (13) · Staphylococcal Skin Infections (11) · Streptococcal Infections (10)
Daptomycin (6) · Vancomycin (4) · Trimethoprim, Sulfamethoxazole Drug Combination (3) · Clindamycin (2) · Linezolid (2) · Mupirocin (2) · chlorhexidine gluconate (2) · 1-phenyl-3,3-dimethyltriazene (1) · ASN100 (1) · Adjuvants, Pharmaceutic (1) · BID protein, human (1) · Cefazolin (1) · Cephalexin (1) · Clopidogrel (1) · Ertapenem (1)
National Institute of Allergy and Infectious Diseases (NIAID) (6) · Bristol-Myers Squibb (2) · Destiny Pharma Plc (2) · LEO Pharma (2) · Lytix Biopharma AS (2) · M.D. Anderson Cancer Center (2) · Melinta Therapeutics, Inc. (2) · Merck Sharp & Dohme LLC (2) · Nabi Biopharmaceuticals (2) · NovaBay Pharmaceuticals, Inc. (2) · Pfizer (2) · AM-Pharma (1) · Andrej Trampuz (1) · Aridis Pharmaceuticals, Inc. (1) · Armata Pharmaceuticals, Inc. (1)
United States (35) · France (7) · Spain (6) · Canada (5) · Czechia (4) · Hungary (4) · Israel (4) · South Africa (4) · Australia (3) · Belgium (3) · Dominican Republic (3) · Germany (3) · Russia (3) · Switzerland (3) · Ukraine (3)
Issam Raad, MD (2) · Seth Hetherington, M.D. (2) · Albert Sotto, MD, PhD (1) · Alexandra Freeman, M.D. (1) · Almena L Free, MD (1) · Andrej Trampuz (1) · Brian S Schwartz, MD (1) · Daisy Blanco, MD (1) · Daisy M Blanco, MD (1) · Daisy M. Blanco, MD (1) · Deborah Birx, MD (1) · Elena M Gonzalez Brant, MD (1)
PMID 17893153, PMID 21537018, PMID 21546629, PMID 22837094, PMID 23099329, PMID 23549582, PMID 25448332, PMID 25785967, PMID 26482312, PMID 26962903, PMID 27025829, PMID 27795368, PMID 28535235, PMID 28657870, PMID 28987525, PMID 30343314, PMID 30587533, PMID 30926187, PMID 32050447, PMID 32271718, PMID 33894131, PMID 34023342, PMID 35578360, PMID 36951472, PMID 37125490, PMID 38066372, PMID 39740667, PMID 40802264, PMID 41433510, PMID 41800789, PMID 41999282
2014 (1), 2016 (1), 2023 (1), 5UM1AI104681-12 (1)